Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT00184639
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany
Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation.
Phase 4
Completed
- Conditions
- Chronic Renal InsufficiencyChronic Kidney Disease
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 16
- Registration Number
- NCT00184769
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Zaragoza, Spain
Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 603
- Registration Number
- NCT00184574
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDelivery SystemsDiabetes Mellitus, Type 2
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT00184613
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark
Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 97
- Registration Number
- NCT00184626
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Efficacy on Height in SGA Children Treated With Growth Hormone
Phase 3
Completed
- Conditions
- Foetal Growth ProblemSmall for Gestational Age
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 151
- Registration Number
- NCT00184756
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Örebro, Sweden
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
Phase 3
Completed
- Conditions
- Adult Growth Hormone DeficiencyGrowth Hormone Disorder
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 86
- Registration Number
- NCT00184730
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 321
- Registration Number
- NCT00184561
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Tianjin, Tianjin, China
Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease
Phase 2
Completed
- Conditions
- End-Stage Renal DiseaseChronic Kidney Disease
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 140
- Registration Number
- NCT00184652
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
Phase 2
Terminated
- Conditions
- Acquired Bleeding DisorderCardiac Surgery Requiring Cardiopulmonary Bypass
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 172
- Registration Number
- NCT00154427
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath